Showing results (401-410 of 426) with videos related to

Sort By:
Pageof 43
Journal of the American College of Cardiology|September 2, 2025
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTORFaiez Zannad, Yogesh N V Reddy, Irina Barash, et al.
American Heart Journal|September 6, 2025
Rationale and Design of the Comparative Effectiveness of ICD Versus Non-ICD Therapy in Contemporary Heart Failure Patients at a Low Risk for Arrhythmic Death (CONTEMP-ICD) trialIlan Goldenberg, Wojciech Zareba, Justin A Ezekowitz, et al.
Journal of Cardiac Failure|June 8, 2013
Acute decompensated heart failure: update on new and emerging evidence and directions for future researchMichael M Givertz, John R Teerlink, Nancy M Albert, et al.
European Journal of Heart Failure|July 3, 2025
Changes in natriuretic peptide levels following patiromer-enabled optimization of medical therapy in heart failure: A post hoc analysis of the DIAMOND studyAndreas P Kalogeropoulos, Ishaque Hameed, Stefan D Anker, et al.
The Canadian Journal of Cardiology|May 24, 2011
The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative careRobert S McKelvie, Gordon W Moe, Anson Cheung, et al.
Circulation|April 28, 2021
Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 CountriesIsabelle Johansson, Philip Joseph, Kumar Balasubramanian, et al.
European Heart Journal|August 30, 2025
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trialJaved Butler, Francesco Fioretti, Ciaran J McMullan, et al.
JACC. Advances|May 30, 2023
Sex-Based Differences in Severe Outcomes, Including Cardiovascular Hospitalization, in Adults With COVID-19 in Ontario, CanadaBahar Behrouzi, Atul Sivaswamy, Anna Chu, et al.
Lancet (London, England)|September 2, 2025
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trialJaved Butler, Ciaran J McMullan, Kevin J Anstrom, et al.
The Canadian Journal of Cardiology|December 4, 2012
The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failureRobert S McKelvie, Gordon W Moe, Justin A Ezekowitz, et al.
Pageof 43